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ABSTRACT 
INCIDENCE OF REJECTION, MORBIDITY, MORTALITY AND GRAFT 
FUNCTION IN RENAL TRANSPLANT RECIPIENTS FOLLOWING 
CYCLOSPORINE TO AZATHIOPRINE SWITCH. Laurie-Ann Nessralla, 
Margaret J. Bia, M.D., Section of Nephrology, Department of 
Internal Medicine, Yale University, School of Medicine, New 
Haven, CT. 
Cyclosporine and azathioprine are immunosuppressive 
agents used in the treatment of kidney graft recipients. 
Cyclosporine interferes with the production of lymphokines 
Interleukin-1 and Interleukin-2. Azathioprine interferes 
with the process of blastogenesis of T-lymphocyte clones. 
Cyclosporine has been shown to be a superior 
immunosuppressive agent when compared to azathioprine. It 
has also been shown, however, that cyclosporine also causes 
a rise in serum creatinine concentration values, a reduction 
in the glomerular filtration rate, tubular injury, 
interstitial fibrosis, hirsutism, liver disease, 
hypertension and gastrointestinal symptomatology. Side 
effects such as these cause one to question whether 
cyclosporine should be used in conjunction with prednisone 
as the sole immunosuppressive post-transplantation, or 
should a switch to azathioprine-prednisone occur. In cases 
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of renal and non-renal toxicity, a switch to azathioprine- 
prednisone should occur. 
It had been the policy of Yale-New Haven Hospital 
between December 1983 to July 1986 to switch renal 
transplant patients from cyclosporine-prednisone to 
azathioprine-prednisone immunosuppressive treatment between 
3-21 months post-transplantation to prevent side effects 
such as those mentioned above. The present investigation 
was performed to evaluate the clinical course of 24 such 
cadaveric renal transplant patients that underwent this 
switch therapy to investigate the incidence of acute 
allograft rejection following the switch as well as renal 
function and graft survival at 6, 12, 18, 24, 30, 36 and >36 
months post-transplantation. 
Results indicate that 42% of patients investigated 
experienced a rejection post-switch which was usually mild. 
Although rejections were usually mild, 3 patients 
experiencing a rejection post-switch eventually lost their 
grafts. Factors such as age, sex, race, presence of 
diabetes mellitus, the presence of a rejection before the 
switch, time of switch post-transplantation, and renal 
function before the switch were investigated and found to 
have no association with an increased frequency of rejection 
post-switch. Improvement in renal function was especially 
evident in those patients who did not suffer a rejection 
post-switch. Thus, it is seen that an immunosuppressive 
switch cannot be undertaken without caution. 
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INTRODUCTION 
Cyclosporine and azathioprine are immunosuppressive 
agents used in the treatment of kidney graft recipients. 
Cyclosporine is a fungal polypeptide which inhibits T-cell 
proliferation. Cyclosporine also interferes with the 
production of lymphokines such as Interleukin-1 and 
Interleukin-2. Azathioprine, an imidazole derivative, 
prevents the expansion of T-lymphocyte clones in their 
response to foreign antigens by interfering with 
blastogenesis. Both cyclosporine and azathioprine are used 
as potent immunosuppressive agents following various 
transplant procedures. When considering kidney allograft 
recipients, there is a risk of nephrotoxicity, renal 
scarring, and a high cost factor associated with the long- 
term use of cyclosporine. It had been the policy of Yale- 
New Haven Hospital from December 1983 to March 1986 to 
switch kidney graft recipients from cyclosporine-prednisone 
to azathioprine-prednisone immunosuppressive treatment at 
3-21 months post-transplant to avoid the nephrotoxicity of 
cyclosporine. 
In examining cyclosporine and azathioprine more 
closely, cyclosporine has been shown to be a more potent and 
effective immunosuppressive agent following transplantation 
procedures. The mechanism of action of cyclosporine is 
controversial but has been extensively investigated. 
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Ferguson et. al monitored the immunosuppressive effect of 
cyclosporine by assaying the proliferative responses of both 
patient and normal lymphocytes cultured in the presence of 
patient plasma obtained at various intervals following an 
oral dose of cyclosporine. Results indicated that 
initially cyclosporine exhibited extensive immunosuppressive 
effects which correlated with a rapid increase in 
cyclosporine levels detected in the peripheral blood. 
Inhibition of lymphocyte proliferation, however, continued 
despite an increased time period post-dose of cyclosporine. 
This demonstrated the presence of decreased lymphocyte 
activity and therefore immunosuppressive characteristics 
following a single oral dose of cyclosporine.^ 
Lafferty et. al have proposed two different models 
. . . . 9 
concerning the site of action of cyclosporine. The first 
model, the subset model, suggests that different populations 
of T-lymphocytes exhibit different sensitivities to 
cyclosporine. T-helper and T-cytotoxic lymphocytes are 
primarily affected by cyclosporine, while T-suppressor cells 
remain unaffected. The T-helper cells are thought to be the 
main site of action of cyclosporine, due their necessity in 
the activation of the cytotoxic subset which is therefore 
indirectly affected by cyclosporine.'^'^ The second model, 
the signaling model, postulates that cyclosporine interferes 
with the transmission of the antigen specific signal to the 
cell interior at some stage following antigen binding. 
It has been experimentally found, however, that cyclosporine 
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does not inhibit antigen binding, the synthesis of 
lymphokines within the cell, or the export of the 
lymphokines from the cell. Thus, cyclosporine interferes 
with the transmission of the antigenic signal to the nucleus 
of the cell which as a consequence interferes with 
Interleukin-1 and Interleukin-2 production by the T-helper 
7 
cells. Later, Cohen et. al reported that one year graft 
survival rates in those renal graft recipients using 
cyclosporine alone was 70-80%, and cyclosporine was thus a 
successful and effective immunosuppressive agent.® In 
summary, cyclosporine exerts its main effect upon 
immunosuppression through selectively inhibiting T-helper 
cell production of Interleukin-1 and Interleukin-2 growth 
factors that are essential for B-cell and cytotoxic T-cell 
differentiation and proliferation, while permitting the 
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expansion of suppressor T-cells. It is clear from the 
evidence presented that cyclosporine has a very different 
mechanism of action when compared to azathioprine which has 
its main effect in blastogenesis. Azathioprine exerts its 
main effect via its metabolism effects. Azathioprine is 
metabolized in the liver to 6-mercaptopurine which 
interferes with normal purine metabolism and thus DNA 
synthesis and cell proliferation. It has, however, been 
proven that cyclosporine is toxic to the kidney and produces 
renal scarring which is inevitably accompanied by 
• • .1 deteriorating renal function. Myers et. al evaluated 
glomerular filtration in 17 recipients of heart transplants 
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who were treated for twelve months or longer with 
cyclosporine. The control group was made up of 15 heart- 
transplant recipients who were treated with azathioprine and 
who had also survived for at least 12 months. Serum 
creatinine concentrations were similar in the two groups at 
the time of transplantation, but these levels rose from 
1.3+O.lmg/dL to 2.1+0.2mg/dL in the cyclosporine group and 
declined from 1.3+O.lmg/dL to 1.0+0.4mg/dL in the 
azathioprine control group at one year post- 
transplantation. This rise in the serum creatinine 
concentration in the cyclosporine group was accompanied by a 
50 percent reduction in the glomerular filtration rate, a 
slight impairment of both proximal and distal tubular 
function, and a histopathological demonstration of atrophic 
tubular injury accompanied by interstitial fibrosis.^ These 
events were not experienced in the azathioprine treated 
control group. Two patients in the cyclosporine treatment 
group developed end-stage renal failure requiring dialysis. 
It was thus concluded that long term cyclosporine therapy is 
associated with irreversible and potentially progressive 
nephropathy.^ Myers et. al conducted this study on heart 
transplant recipients which illustrated the destructive 
effects of cyclosporine on the intact kidneys of these 
patients, and thus forms a basis for concern regarding such 
destructive effects on the kidney in renal transplant 
recipients. 
Similar reports concerning nephrotoxicity associated 
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with long-term cyclosporine use have been documented in 
renal transplant patients. Hunsicker has reported the 
results from five United States transplant centers and one 
Canadian center which used cyclosporine-prednisone in the 
treatment of kidney transplant recipients before this drug 
was released for universal use.^® Thus, these centers are 
able to report the minimum of a two year follow up time 
describing the long-term effects of cyclosporine treatment. 
Hunsicker reports that graft survival in recipients of first 
transplants treated with cyclosporine to be 7-9% better at 
all time intervals following transplantation.^® Four out of 
five U.S. centers and the Canadian center reported a one 
year patient survival of 92-96% of patients treated with 
cyclosporine-prednisone. One year graft survival was 
reported as 73%+2%, which was a gain of 25-30% over 
conventional azathioprine-prednisone immunosuppression.^® 
Hunsicker concluded that cyclosporine treatment following 
renal transplantation will improve the survival of first 
cadaveric renal grafts by 10% at 10 one year.-^^ This 
statement. however, is debated by the Minnesota Trial 
11 Group. The Minnesota Trial Group reported that the 
advantage seen in graft survival by the six centers 
initially using cyclosporine was lost by three years 
post-transplantation.^^ The Minnesota randomized trial 
involved 131 patients in the cyclosporine-prednisone group. 
In this group, 19% of patients were switched to 
azathioprine-prednisone treatment, and 35% had azathioprine 
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added to their immunosuppressive regimen with a concomitant 
lowering of the cyclosporine dose because of 
• • 1 1 
nephrotoxicity. Thus, this group concluded that 
cyclosporine should be used in most renal allograft 
recipients in combination with azathioprine in order that a 
lower dose of cyclosporine can be employed and side effects 
of cyclosporine minimized. 
The risk of nephrotoxicity, possible renal scarring, 
hirsutism, hypertension, liver disease and gastrointestinal 
symptomatology associated with cyclosporine use, raises 
questions addressing whether it should be the sole 
immunosuppressive used in conjunction with prednisone 
post-transplantation, or whether a switch to azathioprine 
and prednisone should occur. In cases of renal toxicity as 
indicated from elevated serum creatinine concentrations, and 
non-renal toxicity, a switch to azathioprine-prednisone 
treatment is often considered. Gonwa et. al have 
demonstrated that patients other than primary cadaveric 
transplants with stable renal function (i.e. defined as 
serum creatinine concentrations less than 2mg/dL), switched 
to azathioprine-prednisolone at an average of 7.97 months 
post-transplantation, had severe problems of graft loss 
post-switch. Those patients who were retransplants, those 
who exhibited prolonged poor renal function post¬ 
transplantation, or those who were classified as non- 
responsive rejection patients were problematic post-switch. 
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The immunosuppressive conversion resulted in graft loss in 
these patients and sometimes patient loss.^ 
Similar results were obtained from Rocher et. al who 
switched 10 patients at 50 days post-transplantation and 19 
patients at 8 months post-transplantation from treatment 
with cyclosporine to azathioprine.All patients had a 
creatinine greater than 2mg/dL before conversion which 
decreased post-conversion. A beneficial creatinine 
response, however, was accompanied by a 22% graft loss 
post-switch in the patients switched at 8 months post¬ 
transplantation, and a 10% graft loss post switch in those 
patients switched at 50 days post-transplantation. Thus, 
the authors concluded that conversion at least 2 months 
post-transplantation is usually successful when assessed by 
short term improvement in renal function, but the risk of 
graft morbidity is substantial if a conversion is 
undertaken. 
Some protocols, however, use only cyclosporine in 
immunosuppressive treatment. Chapman and Morris compared 
two patient groups post-transplantation.^^ One group only 
received cyclosporine treatment, and the other group 
received azathioprine-prednisolone treatment. Graft 
survival was significantly better in the cyclosporine 
treated group. However, 48% of cyclosporine treated 
patients required dialysis during the first seven days post¬ 
transplantation compared with 31% of azathioprine- 
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prednisolone treated patients. Urine output in the first 24 
hours post-transplantation indicated that 33% of all 
cyclosporine patients (67% of those requiring dialysis) 
passed urine initially, but subsequent dialysis was needed 
due to allograft dysfunction. Also, 16% of cyclosporine 
patients did not pass urine in the initial period following 
transplantation. Thus, cyclosporine patients required 
dialysis in the first week post-transplantation more than 
azathioprine-prednisolone patients due to post¬ 
transplantation occurrences such as nephrotoxicity, and not 
directly due to donor variables.Serum creatinine 
concentration was also found to be significantly higher in 
the cyclosporine treated group when compared to the 
azathioprine-prednisolone patients, until a switch from 
cyclosporine to azathioprine-prednisolone occurred. The 
conversion caused a slow but progressive decrease in serum 
creatinine concentration in previously treated cyclosporine 
patients. 
The investigators mentioned thus far have indicated a 
cyclosporine-prednisone to azathioprine-prednisone switch 
to be beneficial when attempting to avoid nephrotoxicity, 
but detrimental and risky when considering the graft losses 
that occur post-switch. Adu et. al have recently reported 
the cyclosporine-prednisone to azathioprine-prednisone 
• IS 
switch to be very harmful. These investigators studied 
four patients who were switched at 3 months post¬ 
transplantation. Three of the individuals studied 
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experienced a chronic rejection immediately following the 
switch, and two of these individuals were returned to 
cyclosporine treatment. Thus, Adu et. al have indicated 
that the penalties of rejection and infection following a 
cyclosporine-prednisolone to azathioprine-prednisolone 
switch to be unacceptable. These investigators suggest that 
renal transplant patients remain on a cyclosporine- 
prednisolone regimen as their primary immunosuppressive 
therapy used post-transplantation.^^ 
The present investigation was performed to investigate 
patients at Yale-New Haven Hospital who were switched from a 
cyclosporine-prednisone to an azathioprine-prednisone 
regimen in order to examine our own experience with this 
protocol. 
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To evaluate the clinical course of cadaveric renal 
transplant recipients converted from maintenance therapy 
with cyclosporine-prednisone to azathioprine-prednisone 
treatment within the first 21 months after transplant, 
the incidence of acute allograft rejection after the switch 
as well as renal function and graft survival at 6 months, 
1 year, 18 months, 2 years, 30 months, and 3 years were 
examined. 
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MATERIALS AMD METHODS 
PATIENT POPULATION 
Cyclosporine was first made available for use at Yale- 
New Haven Hospital in December 1983. It was initially used 
only in high risk renal cadaveric recipients. Within 9 
months, it was being used in all cadaveric recipients. Most 
patients originally started on prednisone and cyclosporine 
were switched to prednisone and azathioprine within 3-21 
months post-transplantation to prevent chronic interstitial 
fibrosis. This policy for cyclosporine use was followed 
from December 1983 to July 1986. During this time period, 
59 cadaveric renal transplants were performed. Of these, 35 
were eliminated from evaluation because of early graft loss, 
death, or failure to be placed on cyclosporine initially 
following transplantation. This left 24 patients initially 
started on cyclosporine and maintaining a functional graft 
3-21 months post-transplantation. Since most patients were 
treated similarly, there existed no control population of 
patients who remained on cyclosporine alone and who were not 
converted to azathioprine. In the years prior to the 
introduction of cyclosporine, all cadaveric renal transplant 
recipients were started and continued on an azathioprine- 
prednisone protocol. Comparing these patients to the 
current population would also not represent a meaningful 
control group since initial graft success is different with 
cyclosporine compared to azathioprine. Therefore, in this 
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retrospective analysis, no control group could be used. 
Rather, each patient served as his or her own control for a 
rejection and assessment of renal function in the before 
versus after switch period. 
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Twenty-four patients (see Figure 1) , all of whom were 
switched from cyclosporine-prednisone to azathioprine- 
prednisone, form the basis of the present investigation. In 
order to determine the effects of the conversion on graft 
function, graft rejection and graft survival, a 
retrospective chart review was undertaken. The data 
collected were obtained from in-patient and out-patient 
records, laboratory sheets, and the personal files as well 
as communication with Drs. Margaret Bia, Alan Kliger, Karen 
Gaudio and Norman Seigel. 
Patient characteristics such as age, history of 
diabetes, prior loss of a kidney graft, and number and 
severity of rejections prior to conversion were analyzed to 
see if any of these factors influenced the patient's course 
post-conversion. Diabetes is taken into special 
consideration because of its association with poorer patient 
survival compared to non-diabetics receiving renal 
transplants. Renal function post-transplantation and post¬ 
conversion was assessed according to serum creatinine 
concentration and blood urea nitrogen (BUN) levels at 6, 12, 
24, 30, and 36 months after transplant, and at 6, 12, 18, 
and 24 months post-conversion. Cyclosporine trough levels 
were measured by high pressure liquid chromatography (HPLC). 
The incidence of rejection both before and after the 
conversion was also evaluated. Rejection was defined as an 
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increase in serum creatinine concentration responsive to 
treatment with high intravenous doses of solumedrol. In 
most cases examined, rejection was confirmed by renal 
biopsy. Rejection was determined as mild if the patient 
received solumedrol alone, and severe if they required 
additional treatment with antilymphocyte globulin (ATG), or 
0KT3 monoclonal antibodies. 
A causal relationship between cyclosporine-azathioprine 
conversion and a subsequent rejection or graft loss was 
assessed by noting the time of the conversion, the time 
post-transplantation that the conversion took place, the 
time the rejections occurred after the switch, and renal 
function post-conversion. The amount of overlap of 
concomitant azathioprine with cyclosporine treatment during 
each switch was also noted. Patients who rejected or lost 
their graft post-conversion were compared to those who did 
not for differences in factors that may have predisposed 
them to a poor response post-conversion such as the number 
of rejections before the switch, primary or second 
transplant, diabetes mellitus, and renal function before the 
switch. 
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STATISTICAL ANALYSIS 
Statistical analyses of the data were made utilizing 
life table preparations, Chi-Square analyses, and the Simple 
T-Tests. All results are presented as the mean + the 
standard deviation of the mean. 
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RESULTS 
THE PATIENT POPULATION 
The population of 24 cadaveric recipients evaluated 
constituted 40.6% of all cadaveric transplants performed and 
51% of all cadaveric transplant patients begun on 
cyclosporine during the 27 month time period indicated 
(Figure 1) . Of the 47 patients initially begun on 
cyclosporine-prednisone immunosuppressive therapy, 17 
patients never reached the time period post-transplantation 
in which they could be switched because of severe rejection 
(10 patients), graft loss from technical difficulties (4 
patients), or discontinuation of immunosuppression due to 
infection (3 patients). Six patients reached the switch 
point but were never switched due to allergic reactions to 
azathioprine in one patient, loss of follow-up in two 
patients, deteriorating renal function in one patient, and 
M.D. philosophy in two patients. Thus, the cyclosporine- 
prednisone switch patients represent only a fraction of the 
total number of transplants performed between December 1983 
and March 1986. They represent a group of patients 
initially started on cyclosporine and maintaining a graft 
survival for three months or more post-transplantation. 
These patients were followed for a mean of 27.25+9 months 
with a range of 13-43 months. Twelve patients were followed 
13-24 months, and twelve patients were followed 26-43 
months. 
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ANALYSIS OF PRE-SWITCH CHARACTERISTICS 
The background characteristics of all 24 cadaveric 
renal transplant recipients in the present investigation 
were examined. Data presented in Table I indicates that the 
majority of the patients studied were primary cadaveric 
graft recipients (20 vs 4) . Only 7 patients (29%) had 
diabetes mellitus. Mean creatinine concentration prior to 
switch was 2.0+0.7 mg/dL with 8 patients having a creatinine 
concentration >2.5 mg/dL. Almost two-thirds of all patients 
had experienced at least one rejection prior to switching. 
Four patients had experienced 2 rejections prior to the 
switch. In 9 of the 15 patients that suffered a rejection 
prior to the switch, the rejection was severe requiring ATG 
or 0KT3 after pulse steroid treatment. Most patients (83%) 
were switched because of protocol to avoid future 
nephrotoxicity. Only 4 patients (17%) were perceived as 
being nephrotoxic as the immediate reason for the switch. 
Most patients were switched by overlap which consisted of a 
concomitant administration of azathioprine and cyclosporine 
for a period of 5-7 days in which the cyclosporine trough 
level value in the patient population at the time of the 
switch was within the therapeutic range of 50-150 ng/ml as 
measured by high pressure liquid chromatography (HPLC). 
Patients were switched from a cyclosporine dose of 12.6+6.0 
mg/kg/day to an azathioprine dose of 2.0+0.35 mg/kg/day. 
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Figure 2 illustrates the distribution of the 24 
patients studied concerning the time of the 
immunosuppressive switch post-transplantation. Seventy-five 
percent of the 24 patients studied switched 
immunosuppressive therapy between 2.75 and 7 months post¬ 
transplantation. Fourteen patients (58%) were switched at 6 
months or greater than 6 months post-transplantation, and 2 
patients were switched after 11 months post-transplantation. 
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ANALYSIS OF RESPONSE TO SWITCH; REJECTION 
Ten patients (42%) had an acute rejection at some point 
following the switch from cyclosporine to azathioprine. In 
eight of the ten patients (80%) the rejection was mild and 
occurred only once. One patient suffered a single severe 
rejection, and one patient suffered both a mild and severe 
rejection following the switch. Eighty percent of these 
rejections occurred between 1 week and 7 months post-switch. 
Three patients had more than one rejection post-switch. 
Three rejections occurred less than 1 month post-switch and 
4 rejections (40%) occurred within 3 months post-switch 
(Table II) . All patients responded to rejection treatment 
in which their rejection was resolved except for the one 
patient, X.X., that suffered a severe rejection post-switch. 
This patient ultimately lost her graft due to her inability 
to resolve the rejection. 
Factors were compared in the 10 patients with a 
rejection post-switch versus the 14 without to determine if 
any characteristic was associated with a risk for rejection 
post-switch. The frequency of these characteristics was 
compared by the Fisher's Exact Test. As seen in Table III, 
there was no difference between the groups in age, sex, 
race, presence of diabetes mellitus, presence of a rejection 
before switch, time of switch or renal function before the 
switch. There was also no relationship (by linear 
regression analysis) of the number of rejections before the 
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switch and the number of rejections following the switch. 
Thus, there was no characteristic or factor which was 
associated with an increased frequency of rejection post¬ 
switch. 
Analyzed in another way, mean patient age, mean time of 
switch post-transplantation and mean renal function at the 
time of the switch were compared in patients with versus 
patients without a rejection post-switch (Table IV) . As 
seen in Table IV, these variables were nearly identical in 
the 10 patients experiencing a rejection post-switch 
compared to the 14 patients free of a rejection after the 
switch. 
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RESPONSE TO SWITCH; RENAL FUNCTION 
To assess graft function, creatinine concentrations at 
6, 12, 18, 24, 30, 36 and greater than 3 6 months post¬ 
transplantation and post-switch were examined in the 2 4 
cadaveric renal transplant patients as a whole. Renal 
function was also compared in patients who experienced a 
rejection post-switch and those who did not. Figure 3 
illustrates the mean creatinine concentration values at 
various intervals post-transplantation for the patient 
population as a whole. Renal function was well preserved in 
most patients except for 3 patients whose creatinine 
concentration values rose above 3.0 mg/dL at 2 years post¬ 
transplant. The mean serum creatinine concentration at 2 
years post-transplantation for the group as a whole was 
2.3+1.0 mg/dL. 
Renal function was compared in patients who suffered no 
rejections of any kind post-switch and in those who 
experienced a post-switch rejection (Figures 4 & 5). There 
was a tendency for serum creatinine concentrations to be 
higher in patients who suffered a rejection post-switch, but 
the difference did not reach statistical significance (by 
Student's T-Test), The tendency toward a higher mean 
creatinine at year 2 in the rejection group is attributable 
to the 3 patients with serum creatinine values of 3.2, 4.0, 
and 4.9 mg/dL. 
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These three patients clearly did not benefit from the 
immunosuppressive switch. Patient X.X. was switched 5 
months post-transplantation and suffered one rejection prior 
to the switch. This patient suffered a severe rejection 
after which normal renal function was never restored and she 
ultimately lost the graft at 28 months post-switch. The 
pattern of her graft loss was most consistent with a chronic 
rejection process. The second patient with markedly 
impaired graft function post-switch, Y.Y., suffered two 
rejections following the switch at 19 and 20 months post¬ 
transplantation, respectively. Patient Y.Y. was switched 
from cyclosporine to azathioprine at 4 months post¬ 
transplantation. This patient had also suffered a severe 
rejection prior to the switch and had a serum creatinine 
concentration of 8.9 mg/dL at the conclusion of this study. 
Patient Y.Y. eventually started dialysis treatment four 
months after this study was completed. The last patient to 
exhibit serum creatinine concentrations 3.0 mg/dL post¬ 
switch, Z.Z., also eventually lost his graft at 31 months 
post-transplantation. Patient Z.Z. had suffered 1 severe 
rejection prior to the switch, and a mild and severe 
rejection following the switch. The first of these two 
rejections occurred 1 week post-switch, the second at two 
months post-switch. These rejections were resolved which 
leads one to suspect that the eventual graft loss that 
occurred at 31 months post-transplantation was due to a 
chronic rejection process. 
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When one analyzes mean serum creatinine concentration 
values in the time interval after switching (not time post¬ 
transplantation seen in Figure 5) in rejectors versus post¬ 
switch non-rejectors, there is a tendency for serum 
creatinine concentrations to be higher in patients with a 
rejection, but the difference fails to reach statistical 
significance (Figures 6 & 7). There was also a tendency for 
creatinine concentrations to fall after the switch to 
azathioprine, a tendency that was more obvious in patients 
without a rejection. This tendency was apparent by the 
first month post-switch. 
Individual serum creatinine concentrations for post¬ 
switch rejectors and non-rejectors illustrates that the 
post-switch rejectors display deteriorating renal function 
at successive time intervals post-transplantation (Figures 
8a and 8b). After 12 months post-transplantation, 11 out of 
14 (79%) post-switch non-rejectors had serum creatinine 
values <2.0 mg/dL. This is in sharp contrast to the 
patients experiencing rejection post-switch in which only 5 
out of 10 (50%) patients had a creatinine <2.0 mg/dL after 
12 months post-transplantation. 
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RESPONSE TO SWITCH; GRAFT SURVIVAL 
Cumulative survival data is presented in life tables 
in Figures 9 and 10. Figure 9 presents actuarial patient 
survival. One year patient survival was 100%. Two and 
three year patient survival dropped to 79% due to the death 
of three patients between 1 and 2 years. One patient, A.A., 
a severe alcoholic, died at 20 months post-transplantation 
due to severe pneumonia and expired with a functioning 
graft. The second patient, B.B., died at 24 months 
following transplantation due to a massive myocardial 
infarction with chronic sepsis due to a liver abscess. This 
patient's death was unrelated to the kidney graft. The 
third patient, C.C., expired at 2 years post-transplantation 
due to severe gastrointestinal bleeding. This patient had 
lost her kidney graft at 18 months post-transplantation and 
died while receiving dialysis treatment. 
Actuarial one year graft survival was 100% (Figure 10). 
At two years, graft survival decreased to 79.5% due to the 
loss of 4 grafts: 3 losses due to patient death, and 1 loss 
due to a chronic rejection. At 36 months, graft survival 
decreased again to 58% due to the loss of two more grafts 
due to chronic rejection. 
Looking at the patient population as a whole, 3 
patients (12%), experienced graft loss at 18 to 33 months 
post-transplantation. The frequency of patients that 
experienced a graft loss following the immunosuppressive 
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switch was 12%. Finally, the incidence of rejection was 42% 
in the population of patients studied. 
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DISCUSSION 
This study was performed to analyze the safety and 
efficacy of switching transplant patients from cyclosporine 
to azathioprine. A switch from cyclosporine-prednisone to 
azathioprine-prednisone would avoid the long-term 
nephrotoxic effect of cyclosporine along with its cost, 
hirsutism side effect and a multitude of other problems. Do 
patients benefit if such a switch is undertaken? This is 
the basic question that the present investigation set out to 
evaluate. Since 42% of the patients that do switch 
immunosuppressive therapy suffer a rejection following the 
switch (occurring at 6 months to 33 months post¬ 
transplantation) , it may seem risky to switch. If, however, 
one appreciates that acute cellular mild rejections 
accounted for 90% of these rejections then such an 
immunosuppressive switch may not appear to be a life 
threatening or graft threatening procedure, despite the 
potential for rejection which follows. 
Eighty percent of these post-switch rejections occurred 
between 1 week and 7 months post-switch with 30% occurring 
at 1 week post-switch (Table II) . It seems likely that the 
switch can be implicated in rejections occurring within one 
week of the switch. The three patients that rejected at 1 
week post-switch were at 6, 7, and 9 months post¬ 
transplantation. This is an unusual time to have a 
spontaneous rejection. and it makes it likely that the 
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rejection was related to the switch. It is less clear 
whether the rejections occurring after this period are 
related to the switch. Patients rejecting 3.5-28 months 
after the switch are probably experiencing rejection at a 
higher frequency than would be expected 19 to 33 months 
post-transplantation, but without a control group of 
patients maintained on cyclosporine, this is difficult to 
analyze. 
Shen et. al studied 37 patients who were switched from 
cyclosporine-prednisone to azathioprine-prednisone 
immunosuppressive therapy at 6 months post- 
transplantation.-^' These investigators found that the 8/37 
(22%) rejections that occurred following the switch were 1-3 
months following the switch and are therefore likely to have 
been linked to the switch. They concluded that there is an 
increased risk of acute rejection following the conversion. 
A high post-switch rejection frequency was also observed by 
no , , 
Vanrenterghem et. al. These investigators switched 9 
patients at one month post-transplantation and 9 patients at 
3 months post-transplantation. Data obtained indicated that 
90% of patients switched at 1 month post-transplantation 
suffered an acute cellular rejection at 1 week post- 
.no , , 
switch. If patients were switched at 3 months post¬ 
transplantation, the rejection rate declined to 78% but was 
still high. Thus, it was concluded that an 
immunosuppressive switch was associated with a high 
incidence of acute cellular rejection immediately following 
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• 18 the switch. These authors then proposed that maintaining 
patients on lower doses of cyclosporine would avoid the 
nephrotoxic effects of cyclosporine on the kidney without 
compromising graft acceptance. Milford et. al have reported 
similar results concerning switch data.^^ Fifteen of fifty- 
two patients switched from cyclosporine to azathioprine 
(28%) between 4 and 6 months post-transplantation 
experienced acute cellular rejection after the switch which 
was, however, easily controlled. These investigators 
conclude that the conversion is possible, but not risk free 
to the patient and the graft. 
Data from Shen, Vanrenterghem and Milford clearly 
suggest that switching from cyclosporine to azathioprine too 
early post-transplantation may be associated with acute 
rejection, but in the present study no relationship was 
found between the time of switch post-transplantation and 
the frequency of rejection post-switch. Our failure to 
document a correlation may be due to the small numbers 
evaluated. Our frequency of post-switch rejection was 
similar to that described by Shen and Milford, but lower 
than that described by Vanrenterghem. 
Concerning renal function in these patients, the 
patient population as a whole maintained a stable serum 
creatinine concentration under 2 mg/dL up to 18 months post¬ 
transplantation (Figure 3). The mean values tend to 
increase after this time interval, but this is mainly due to 
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one patient, Y.Y., whose deteriorating renal function 
affected the mean value of the decreasing sample size 
considerably. There was a general tendency for serum 
creatinine concentrations to decrease following the switch. 
These data suggest that the switching may improve renal 
function in most transplant patients. Patients experiencing 
a rejection post-switch were more likely to experience a 
deterioration in renal function (Figure 8b). Renal function 
deteriorated in an additional 3 patients even though no 
post-switch rejection occurred (Figure 8a). Again, without 
a control group remaining on cyclosporine, it is difficult 
to know whether this loss of graft function is greater than 
what would have occurred had the patients remained on 
cyclosporine. 
Discussing the results of Shen et. al once more, these 
investigators found that the initial response to the switch 
was a 24% decrease in serum creatinine concentration values 
and therefore an improvement in renal function. This 
improvement, however, was only seen in patients who did not 
suffer an acute cellular rejection following the 
immunosuppressive switch. Similar results have been 
reported by Milford et. al. In this investigation 
previously described, 52 patients were switched from 
cyclosporine to azathioprine 4-6 months following 
transplantation. Fifty of these 52 patients (96%) 
maintained functioning grafts and experienced a 20% mean 
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reduction in their serum creatinine concentrations over a 9 
to 22 months time period. 
Further studies by Maddux et. al also demonstrate a 
substantial decrease in serum creatinine concentration 
values post-switch.^® In this investigation, 21 patients 
were switched from cyclosporine to azathioprine between 2 
weeks and 9 months post-transplantation. Renal function was 
significantly improved (p<0.05) at 6 months post-switch when 
compared with pre-switch serum creatinine concentration 
values. All patients switched experienced an improvement in 
renal function. These investigators also found no 
difference in the rate of rejection in switched patients 
when compared with non-switched matched controls. They 
conclude that the switch is safe and improves renal 
function. In our study we also observed a trend for 
creatinine concentrations to decrease following the switch 
to azathioprine, but the trend was apparent only in patients 
not experiencing a rejection (Figures 6 & 8a). 
One year patient survival in the population was 100% in 
the present investigation. It dropped to 79% at 2 years due 
to the deaths of three patients from infection and 
gastrointestinal bleeding and remained at 79% at 3 years. 
Graft survival was also excellent (100% at 1 year and 79.5% 
at two years) but fell to 58% at 3 years (Figures 9 & 10) . 
These grafts were all lost due to acute or chronic rejection 
after the switch. Veitch et. al report an actuarial 2 year 
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graft survival of 73% in a group of 42 patients converted 
from cyclosporine to azathioprine at 3 months post- 
transplantation. Similar results have been demonstrated 
by Tegzess et. al who converted 37 cadaveric renal 
transplant patients from cyclosporine to azathioprine at 4 
months post-transplantation.^^ These researchers initially 
used cyclosporine alone in their graft recipients, thus 
observing the direct effects of cyclosporine on the kidney. 
An actuarial graft survival 94% at 1 year, 80% at 2 years, 
and 75% at 3 years post-transplantation. Grafts were lost 
due to rejection episodes. Although no control group was 
followed in this study, these results compare favorably to 
the 1 and 5 year follow-up of patients maintained on 
cyclosporine. Studies of 1 and 5 year graft survival in 
patients maintained on cyclosporine are 84% and 97% one year 
graft and patient survival, respectively.'^'^ This dropped to 
67% and 92% at 3-5 years post-transplantation.^^ These 
researchers report that nephrotoxicity was the only 
persistent long term complication of cyclosporine use. 
Although graft survival in the present investigation 
compares favorably with that described in patients 
maintained on cyclosporine at 2 to 3 years post¬ 
transplantation, the incidence of rejection is higher than 
expected 3-21 months post-transplantation. When all the 
results are viewed together, it can be seen that 37.5% of 
patients either experience a rejection and/or deteriorating 
renal function (creatinine >2.0 mg/dL) post-switch. The 
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data therefore suggests that the immunosuppressive switch 
should be considered with caution. However, since the 
current data has observed a similar graft survival as that 
described with cyclosporine, the question still remains 
whether long-term graft survival and graft function will be 
better preserved in patients switched versus those 
maintained on cyclosporine in whom chronic nephrotoxicity 
might occur. 
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SUmARY 
1. Graft survival in patients switched from cyclosporine to 
azathioprine compares favorably with other studies in 
which patients were maintained on cyclosporine as 
described. 
2. 42% of patients experience a rejection post-switch which 
is usually mild but occurring later in the post¬ 
transplant period than expected, making a causal 
relationship with switch seem likely. 
3. Although rejections were usually mild, 3 patients 
experiencing rejection post-switch eventually lost their 
grafts. 
4. Serum creatinine concentration values post-switch 
remained stable or decreased in 12 patients but 
deteriorated in 6 patients. Four patients suffered 
rejection (2 patients expired). 
5. Improvement in renal function was especially evident in 
those patients who did not suffer a rejection post¬ 
switch. 
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The present investigation has demonstrated that 
following renal transplantation, an immunosuppressive switch 
from cyclosporine-prednisone to azathioprine-prednisone is 
accompanied by both advantages and disadvantages. Thus, the 
immunosuppressive switch cannot be undertaken without 
caution. The author of the present investigation believes 
that an alternative to an immunosuppressive switch exists 
which will avert the nephrotoxic effects of cyclosporine on 
the kidney and maintain adequate immunosuppression. 
Triple therapy involving cyclosporine, prednisone and 
azathioprine now appears to be the solution to the problem 
of cyclosporine nephrotoxicity, avoiding acute cellular 
rejection following the immunosuppressive switch, and 
maintaining allograft acceptance in the renal transplant 
individual. Lorber et. al have studied the effects of an 
immunosuppressive triple therapy regimen upon renal 
allograft acceptance and serum creatinine concentrations 
following transplantation.^^ Fourteen patients, eleven of 
whom were cadaveric renal transplant recipients, were 
treated with cyclosporine-prednisone following 
transplantation. These patients displayed a continued 
elevation in serum creatinine concentration values greater 
than 2.5 mg/dL up to 246+100 days post-transplantation. The 
method of initiation of azathioprine therapy in addition to 
cyclosporine-prednisone therapy involved the introduction of 
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azathioprine over a 5-7 day period to a final dose of 
2 mg/kg/d.Once the azathioprine dose was achieved, 
cyclosporine doses were reduced in 50-100 mg/d until a final 
dose of 2.5-3 mg/kg/d was reached. The results of the 
cyclosporine dose reduction were encouraging. None of the 
14 patients on triple therapy suffered any adverse effects 
to the therapy, none of the patients suffered acute 
allograft rejection, and renal function was improved as 
indicated by decreased serum creatinine concentration 
values. It was observed that serum creatinine 
concentration values decreased in accordance with the 
decrease in the cyclosporine dose over the 5-7 day period. 
The mean serum creatinine concentration value immediately 
preceding the reduction in cyclosporine was 3.7+0.7 mg/dL, 
whereas at 120 days following the initiation of triple 
therapy, the mean serum creatinine concentration value was 
reported to be 2.5+0.4 mg/dL. Thus, it is evident that a 
reduction in cyclosporine doses also reduces the nephrotoxic 
effects of cyclosporine upon the kidney without sacrificing 
adequate immunosuppressive therapy. 
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BACKGROUND DATA FOR 24 RENAL CADAVERIC TRANSPLANT 
RECIPIENTS BEFORE THE CYCLOSPORINE-PREDNISONE TO 
AZATHIOPRINE-PREDNISONE IMMUNOSUPPRESSIVE CONVERSION 
CHARACTERISTIC MEAN VALUE or RANGE 
NUMBER OF SUBJECTS 
CADAVERIC 24 (100%) 
AGE AT TRANSPLANT(yrs) 44.5+13.4 9-64 
LENGTH FOLLOW-UP(mo) 27.25±9 13-43 
DIABETIC vs. NON-DIABETIC 7 (29%) vs. 17 (71%) 
PRIMARY vs. SECOND GRAFT 20 (83%) vs. 4 (17%) 
CREATININE CONC.<lmo 
BEFORE SWITCH (mg/dL) 
2.0±0.7 0.7-0.2 
NO. OF PATIENTS WITH >1 
REJECTION BEFORE SWITCH 15 
TIME SWITCH POST-TPX(mo) 6.7+3.7 2.75-21 
REASON FOR SWITCH: 
PROTOCOL vs. NEPHROTOXICITY 20 (83%) vs. 4 (17%) 
PROTOCOL OF SWITCH*: 
OVERLAP vs. IMMEDIATE 19 (79%) vs. 5 (21%) 
CYCLOSPORINE DOSE SWITCHED 
FROM (mg/kg/d) 12.7+6 5.1-30 
PREDNISONE DOSE SWITCHED 
FROM (mg/kg/d) 0.25+0.163 0.15-1.0 
AZATHIOPRINE DOSE SWITCHED 
TO (mg/kg/d) 2.0+0.35 1.6-3.0 
CYCLOSPORINE TROUGH LEVEL 
IMMEDIATELY PRECEDING 
SWITCH (ng/ml) 58+2 3 18-96 
*Overlap= 5-7 days of Azathioprine with Cyclosporine 
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TABLE II 
REJECTION DATA IN THE 10/24 PATIENTS THAT REJECTED 
POST-SWITCH 
PTS No. REJECTIONS SEVERITY of 
POST-SWITCH REJECTIONS 
POST-SWITCH 




/ \ * (mo) 




/ \ ** (mo) 
D.D. 1 MILD 1 week 6 
Y. Y. 2 MILD 3.5 19 
F.F. 1 MILD 15 21 
G.G. 1 MILD 7 10 
X.X. 1 SEVERE 28 33 
Z.Z. 2 MILD, SEVERE 1 week 7 
H.H. 1 MILD 6 14 
A. A. 1 MILD 5 16 
J. J. 2 MILD 2 9 
K.K. 1 MILD 1 week 9 
*Mean Interval Post-Switch in Which The First 
Rejection Occurred= 6.8+8.7 months. 
"k k 
Mean Interval Post-Transolantation in Which The 
First Rejection Occurred= 14+7 months. 
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RESULTS OF ANALYSIS OF THE FREQUENCY OF CHARACTERISTICS IN 
PATIENTS WHO REJECTED VS. THOSE WHO DID NOT FOLLOWING 
THE IMMUNOSUPPRESSIVE SWITCH 
CHARACTERISTIC FREQUENCY P VALUE* 
AGE; 
<20 yrs vs. >20 yrs at Transplant 1 vs. 23 NS 
<40 yrs vs. >40 yrs at Transplant 8 vs. 16 NS 
<50 yrs vs. >50 yrs at Transplant 16 vs. 8 NS 
<60 yrs vs. >60 yrs at Transplant 21 vs. 3 NS 
Diabetes vs. No Diabetes at Transplant 7 vs. 17 NS 
Any Rejection Before Switch vs. 
No Rejection Before Switch 15 vs. 9 NS 
SWITCH: 
<4 mo vs. >4 mo Post-Transplant 5 vs. 19 NS 
<6 mo vs. >6 mo Post-Transplant 12 vs. 12 NS 
<8 mo vs. >8 mo Post-Transplant 20 vs. 4 NS 
<12 mo vs. >12 mo Post-Transplant 23 vs. 1 NS 
CREATININE fma/dL^: 
<1.0 vs. >1.0 Imo Before Switch 1 vs. 2 3 NS 
<1.5 vs. >1.5 Imo Before Switch 9 vs. 15 NS 
<2.0 vs. >2.0 Imo Before Switch 15 vs. 9 NS 
Male vs. Female 14 vs. 10 NS 
White vs. Black 22 vs. 2 NS 
Primary vs. Second Transplant 20 vs. 4 NS 
Values analyzed using Fisher's Exact Test 
"ic • • • 
NS denotes not significant 
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TABLE IV 
FREQUENCY OF CHARACTERISTICS IN THOSE PATIENTS WHO REJECTED 










PRE-SWITCH 1.0+0.7 0.7+0.7 NS 
TIME OF SWITCH POST¬ 
TRANSPLANTATION 6.5+2.4 mo 7+4.4 mo NS 
CREATININE CONCENTRATION 
IMMEDIATELY PRECEDING 
SWITCH 2.0+1.0 mg/dL 2.0+0.6 mg/dL NS 
Values analyzed using the Student's T-' Test 
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FIGURE 1 
Breakdown of the patient population. Six patients were 
never switched due to allergic reaction (n=l), 
deteriorating renal function (n=l), M.D. philosophy 
(n=2), and a loss to follow-up (n=2). Switch patients 
represent only a fraction of the total: 40% of 
cadaveric transplants, 51% of patients started on 
cyclosporine, and 28.5% of all transplant patients 
during this time period. 
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Total Transplants Performed 12/83 - 3/86 (84) 
Living Related Donor 
Transplants (25) 
Cadaveric Transplants (59) 
Started on Started on 
Azathioprine (12) Cyclosporine (47) 
Patients Patients Never Patients That 
Switched (24) Switched (6) Never Reached 
Switch Point (17) 
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FIGURE 2 
The number of patients switched at various times post¬ 
transplantation is shown here. It is seen that 66% of 
patients were switched between 4 and 7 months post¬ 
transplantation. Twenty-five percent of patients 
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Figure 3 illustrates the mean serum creatinine 
concentrations (mg/dl) post-transplantation in the 
patient population as a whole. The open bars 
represent the mean serum creatinine concentration 
values, whereas the standard deviations below and above 
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FIGURE 4 
Figure 4 illustrates the mean serum creatinine 
concentrations (mg/dl) at various times post¬ 
transplantation in those patients who suffered a post¬ 
switch rejection. Mean values are represented by the 
open bars, whereas the standard deviations below and 
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Figure 5 illustrates the mean serum creatinine 
concentrations (mg/dl) at various times post¬ 
transplantation in those patients who did NOT suffer a 
post-switch rejection. Mean values are represented by 
the open bars, whereas the standard deviations below 
and above the mean are represented by the open squares 
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Figure 6 illustrates the mean serum creatinine 
concentrations (mg/dl) after switching from 
cyclosporine to azathioprine in patients who did not 
suffer a post-switch rejection. The first bar 
represents the mean pre-switch creatinine concentration 
1 month pre-switch. Open bars represent mean values, 
and open squares and open diamonds represent values 
below and above the mean, respectively. 
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FIGURE 7 
Figure 7 illustrates the mean serum creatinine 
concentrations (mg/dl) in patients who suffered at 
least one post-switch rejection. The first bar 
represents the mean pre-switch creatinine concentration 
1 month pre-switch. Open bars represent mean values, 
and open squares and open diamonds represent values 
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Figure 8a illustrates the serum creatinine 
concentration values for the 14 patients that did NOT 
suffer a post-switch rejection. For each patient, bars 
from left to right represent 6, 12, 18, 24, 30, 36 and 
>36 months post-transplantation, respectively. Values 
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FIGURE 8b 
Figure 8b illustrates the serum creatinine 
concentration values for each of the 10 patients that 
did suffer a post-switch rejection. For each patient, 
bars from left to right represent 6, 12, 18, 24, 30, 36 
and >36 months post-transplantation, respectively. 
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FIGURE 9 
Figure 9 is a life table (actuarial method) 
representing 1, 2, and 3 year patient survival. 
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Figure 9 
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Figure 10 is a life table (actuarial 
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